Forbes, B.Foley & Lardner LLP2012-12-182012-12-182009http://hdl.handle.net/2440/74682PATENT: B. Forbes (Assignee: University of Adelaide). US 7488798 (PCT/AU03/00898) filed Jul 11, 2003; published Feb 10, 2009; predicted expiry Jul 11, 2023.Altered IGFBPs are able to bind IGF, but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and to two amino acid motifs found to be important for ECM binding. IGF-1 mediated proliferation of cancer cells have been inhibited by use of the altered IGFBPs.enUS 7488798PCT/AU03/00898Patent0020114475748879826947